Your browser doesn't support javascript.
loading
Exposure to potentially inappropriate medications in Brazilian elderly outpatients with metabolic diseases
Martins, Vanessa dos Santos; Mori, Ana Luiza Pereira Moreira; Dorea, Egidio Lima; Pinto, Gelba Almeida; Hirata, Mario Hiroyuki; Hirata, Felipe Dominguez Crespo; Hirata, Rosario Dominguez Crespo.
  • Martins, Vanessa dos Santos; University of Sao Paulo. School of Pharmaceutical Sciences. Sao Paulo. BR
  • Mori, Ana Luiza Pereira Moreira; University of Sao Paulo. University Hospital. Sao Paulo. BR
  • Dorea, Egidio Lima; University of Sao Paulo. University Hospital. Sao Paulo. BR
  • Pinto, Gelba Almeida; University of Sao Paulo. University Hospital. Sao Paulo. BR
  • Hirata, Mario Hiroyuki; University of Sao Paulo. School of Pharmaceutical Sciences. Sao Paulo. BR
  • Hirata, Felipe Dominguez Crespo; State Center for Technological Education Paula Souza. School of Technology. São Paulo. BR
  • Hirata, Rosario Dominguez Crespo; University of Sao Paulo. School of Pharmaceutical Sciences. Sao Paulo. BR
Braz. j. pharm. sci ; 52(4): 699-707, Oct.-Dec. 2016. tab, graf
Artículo en Inglés | LILACS | ID: biblio-951879
ABSTRACT
ABSTRACT Management of pharmacotherapy in elderly with metabolic diseases is challenging and potentially inappropriate medications (PIMs) are risk factors for drug interactions and adverse events. The exposure to PIMs in elderly outpatients with metabolic diseases and its relationship with polypharmacy and other variables was investigated. PIMs prescribed to 207 elderly patients (aged 60 to 96 years) with metabolic diseases who attended a University Hospital of Sao Paulo city, Brazil, from April/2010 to January/2011, were evaluated. PIMs were detected using both 2003 Beers and 2008 STOPP criteria. The association between PIMs and age, gender and polypharmacy was also examined. 2008 STOPP criteria detected more PIMs (44.4 %) than 2003 Beers criteria (16.0%, p<0.001). Beers detected mainly PIMs antihypertensive (clonidine, 20.0%; doxazosin, 10.0%) and antidepressant (fluoxetine, 15.0%; amitriptyline, 10.0%) PIMs. Medicines used for cardiovascular (aspirin, 53.7%) and endocrine system (glibenclamide, 21.3%) were PIMs more frequently detected by 2008 STOPP. Unlike age and gender, polypharmacy increased the risk of PIMs by both 2003 Beers (OR 4.0, CI95% 1.2-13.8, p<0.031) and 2008 STOPP (OR 6.8, CI95% 3.0-15.3, p<0.001). Beers and STOPP criteria are important tools to evaluate the exposure to PIMs, which is strongly associated with polypharmacy in elderly outpatients with metabolic diseases.
Asunto(s)


Texto completo: Disponible Índice: LILACS (Américas) Asunto principal: Anciano / Factores de Riesgo / Instituciones de Atención Ambulatoria / Enfermedades Metabólicas Tipo de estudio: Estudio de etiología / Factores de riesgo Límite: Anciano / Aged80 / Femenino / Humanos / Masculino País/Región como asunto: America del Sur / Brasil Idioma: Inglés Revista: Braz. j. pharm. sci Año: 2016 Tipo del documento: Artículo País de afiliación: Brasil Institución/País de afiliación: State Center for Technological Education Paula Souza/BR / University of Sao Paulo/BR

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Índice: LILACS (Américas) Asunto principal: Anciano / Factores de Riesgo / Instituciones de Atención Ambulatoria / Enfermedades Metabólicas Tipo de estudio: Estudio de etiología / Factores de riesgo Límite: Anciano / Aged80 / Femenino / Humanos / Masculino País/Región como asunto: America del Sur / Brasil Idioma: Inglés Revista: Braz. j. pharm. sci Año: 2016 Tipo del documento: Artículo País de afiliación: Brasil Institución/País de afiliación: State Center for Technological Education Paula Souza/BR / University of Sao Paulo/BR